Company Overview
Company Type: Public Company
Company Status: Operating Subsidiary
Website: www.biomarkdiagnostics.com
Number of Employees: -
Ticker: 20B (DB)
Year Founded: 2014


Business Description
Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. The company holds an agreement with National Research Council of Canada Industrial Research Assistance Program to support research and development of liquid biopsy assay for the early detection and screening of lung cancer. The company was incorporated in 2014 and is headquartered in Richmond, Canada. Biomark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.

Financial Information (Currency: CAD, in mm) 
Total Revenue
0.2
Market Capitalization
20.6
TEV/Total Revenue
140.1x
EBITDA
(1.8)
Total Enterprise Value
22.0
TEV/EBITDA
NM
EBIT
(1.9)
Cash & ST Invst.
0.2
P/Diluted EPS Before Extra
NM
Net Income
(1.8)
Total Debt
1.6
Price/Tang BV
NM
Capital Expenditure
0.0
Total Assets
0.7
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023

Key Professionals
Name
Title
Bux, Rashid Ahmed Maula
Founder, CEO, President & Director
Huang, Guoyu 
Chief Financial Officer
Cheng, Brian Kai-Ming
Chief Technical Officer & Independent Director
Haince, Jeff 
GM & Chief Scientific Officer

Key Board Members
Name
Title
Bux, Rashid Ahmed Maula
Founder, CEO, President & Director
Cheng, Brian Kai-Ming
Chief Technical Officer & Independent Director
Berkeley, Alfred Rives
Member of Advisory Board
Good, Bill
Member of Media Advisory Board
Ramjiawan, Bramhanand 
Independent Director


Primary Industry Classification
Biotechnology


Primary Office Location
3851 Shell Road Suite 130 | Richmond, BC | V6X 2W2 | Canada
Phone: 604 370 0779   

Parent Company
Biomark Technologies Inc

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.26
Market Cap (mm)
21.6
Open
 0.26
Shares Out. (mm)
83.3
Previous Close
 0.26
Float %
39.3%
Change on Day
0.01
Shares Sold Short (mm)
-
Change % on Day
4.7%
Dividend Yield %
-
Day High/Low
 0.26/ 0.26
Diluted EPS Excl. Extra Items
(0.02)
52 wk High/Low
 0.36/ 0.15
P/Diluted EPS Before Extra
NM
Volume (mm)
-
Avg 3M Dly Vlm (mm)
0.0003
Beta 5Y
0.15


 
Delayed Quote** | Last Updated on Oct-05-2023 12:00 AM (GMT-5)
DB:20B - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Biomark Diagnostics Inc, Prior to Reverse merger with BioMark Cancer Systems Inc.
As of October 29, 2014, Biomark Diagnostics Inc, Prior to Reverse merger with BioMark Cancer Systems Inc. was acquired by Biomark Diagnostics Inc. Biomark Diagnostics Inc develops technologies to increase prediction and accuracy in early diagnosis of cancer. The company was founded in 2007 and is based in Richmond, Canada.

United States and Canada
Life Sciences Tools and Services
-
-
-
BioMark Diagnostic Solutions Inc.

United States and Canada
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
May-04-2022
May-04-2022
Private Placement
Target
Biomark Diagnostics Inc. (DB:20B)


0.99
Nov-21-2019
Dec-16-2019
Private Placement
Target
Biomark Diagnostics Inc. (DB:20B)


0.46
Apr-09-2019
Apr-16-2019
Private Placement
Target
Biomark Diagnostics Inc. (DB:20B)


0.15
May-09-2017
Oct-04-2018
Private Placement
Target
Biomark Diagnostics Inc. (DB:20B)


0.81
Mar-09-2016
Jun-24-2016
Private Placement
Target
Biomark Diagnostics Inc. (DB:20B)


0.44
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Aug-30-2023
Executive/Board Changes - Other
Biomark Diagnostics Inc. Appoints Kevin J. Cosgriff to Its Strategic Advisory Team
Jan-11-2023
Product-Related Announcements
BioMark Diagnostics Inc. Announces Update from Ongoing Clinical Trial Using its Lung Cancer Liquid Biopsy Test as it Prepares for Commercial Launch
Dec-20-2022
Annual General Meeting
BioMark Diagnostics Inc., Annual General Meeting, Dec 20, 2022
Oct-27-2022
Product-Related Announcements
Biomark's Glioblastoma Study Published in Cancers Demonstrates Inhibiting SAT1 Sensitized Cancer Cells Towards Radiation and Chemotherapy
Sep-09-2022
Company Conference Presentations
BioMark Diagnostics Inc. Presents at European Society for Medical Oncology (ESMO) Annual Congress 2022, Sep-09-2022


Advisors
Most Recent Auditor
MNP LLP


Most Recent Auditor
Meyers Norris Penny LLP - MNP LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Aug 29, 2023 01:49 AM
20B
BioMark Diagnostics Inc - Medical Equipment - Deals and Alliances Profile
Reports
35
Wright Investors' Service Inc.

May 23, 2023 01:40 AM
20B
Flow of Funds Report for BioMark Diagnostics Inc - prepared by Wright Investors Service
Notes
66
GlobalData

May 09, 2023 03:58 AM
20B
BioMark Diagnostics Inc - Medical Equipment - Deals and Alliances Profile
Reports
35
GlobalData

Jan 23, 2023 04:59 AM
20B
BioMark Diagnostics Inc - Medical Equipment - Deals and Alliances Profile
Reports
30
GlobalData

Nov 16, 2022 05:41 AM
20B
BioMark Diagnostics Inc - Medical Equipment - Deals and Alliances Profile
Reports
30
GlobalData

Aug 29, 2022 09:31 AM
20B
BioMark Diagnostics Inc - Medical Equipment - Deals and Alliances Profile
Reports
30
GlobalData

May 12, 2022 03:06 AM
20B
BioMark Diagnostics Inc - Medical Equipment - Deals and Alliances Profile
Reports
28
GlobalData

Feb 14, 2022 07:28 AM
20B
BioMark Diagnostics Inc - Medical Equipment - Deals and Alliances Profile
Reports
27
GlobalData

Oct 25, 2021 04:23 AM
20B
BioMark Diagnostics Inc - Medical Equipment - Deals and Alliances Profile
Reports
30
GlobalData

Aug 11, 2021 07:21 AM
20B
BioMark Diagnostics Inc - Medical Equipment - Deals and Alliances Profile
Reports
29


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Biomark Technologies Inc

41,004,167

49.23

10.4

Nov-14-2022


Huang MBA, Guoyu 

4,300,512

5.16

1.1

Aug-30-2023


Bux Investments Ltd.

3,414,000

4.10

0.9

Nov-14-2022


Bux B.Sc., MBA, Rashid Ahmed Maula

1,210,075

1.45

0.3

Sep-13-2023


Grg Consulting Ltd.

642,088

0.77

0.2

Aug-03-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Huang MBA, Guoyu 
4,300,512
239,000
Bux B.Sc., MBA, Rashid Ahmed Maula
1,210,075
1,250

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Grg Consulting Ltd.
642,088
(220,000)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
BioMark Lung Cancer Risk Assessment Test (Future), ELISA Kits, Liquid Biopsy Test (Future), Omics (Future)


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Aug-30-2023
-
Biomark Diagnostics Inc. (DB:20B)
SEDAR
News Releases
32 KB
Aug-28-2023
Jun-30-2023
Biomark Diagnostics Inc. (DB:20B)
SEDAR
Interim Financial Statements
592 KB
Aug-08-2023
-
Biomark Diagnostics Inc. (DB:20B)
SEDAR
News Releases
32 KB
Jul-31-2023
Mar-31-2023
Biomark Diagnostics Inc. (DB:20B)
SEDAR
Annual Financial Statements
854 KB
Jul-25-2023
-
Biomark Diagnostics Inc. (DB:20B)
SEDAR
News Releases
29 KB
Jun-05-2023
-
Biomark Diagnostics Inc. (DB:20B)
SEDAR
News Releases
44 KB
May-31-2023
-
Biomark Diagnostics Inc. (DB:20B)
SEDAR
News Releases
32 KB
May-03-2023
-
Biomark Diagnostics Inc. (DB:20B)
SEDAR
News Releases
40 KB
Mar-16-2023
-
Biomark Diagnostics Inc. (DB:20B)
SEDAR
News Releases
31 KB
Mar-01-2023
-
Biomark Diagnostics Inc. (DB:20B)
SEDAR
News Releases
38 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Bux B.Sc., MBA, Rashid Ahmed Maula (Founder, CEO, President & Director)
Sep-13-2023
Common Shares
1,250
349
Open Market Acquisition
0.10
Multiple
Huang MBA, Guoyu  (Chief Financial Officer)
Aug-30-2023
Common Shares
1,000
284
Open Market Acquisition
0.02
Multiple
Huang MBA, Guoyu  (Chief Financial Officer)
Aug-03-2023
Common Shares
(220,000)
(43,039)
Other Disposition
(4.87)
Multiple
Grg Consulting Ltd.
Aug-03-2023
Common Shares
1,500
301
Open Market Acquisition
0.23
Multiple
Grg Consulting Ltd.
Aug-03-2023
Common Shares
220,000
43,039
Other Acquisition
52.12
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Bux, Rashid Ahmed Maula
Founder, CEO, President & Director
604-370-0779
-

Cheng, Brian Kai-Ming
Chief Technical Officer & Independent Director
604 370 0779
-

Berkeley, Alfred Rives
Member of Advisory Board
604 370 0779
-

Good, Bill
Member of Media Advisory Board
604 370 0779
-
-
Ramjiawan, Bramhanand 
Independent Director
604 370 0779
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Bux, Rashid Ahmed Maula
Founder, CEO, President & Director
604-370-0779
-

Huang, Guoyu 
Chief Financial Officer
604 370 0779
-

Cheng, Brian Kai-Ming
Chief Technical Officer & Independent Director
604 370 0779
-

Haince, Jeff 
GM & Chief Scientific Officer
604 370 0779
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
